文献速递白血病

全球背景下的慢性髓性白血病:日本队列的验证性发现与新发现

Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort.
PubMed 文献 · Leukemia · 2026-10-06

本文综述日本在慢性髓性白血病(CML)无治疗缓解(TFR)领域的研究,区分了验证国际已确立概念的研究与提供新生物学见解的研究。验证性研究证实持续深度分子学反应(DMR)后TFR可行,DMR持续时间比快速达标更重要,且重复停药尝试可行。日本研究还揭示了白血病干细胞持续、达沙替尼相关免疫重塑、遗传免疫遗传决定因素等机制。

要点

  • 持续DMR后TFR可行,DMR持续时间是持久缓解的更重要决定因素。
  • 重复停药尝试可行,支持持续DMR为残留病减少和免疫恢复提供时间。
  • 遗传免疫遗传背景、免疫能力、白血病干细胞持续和治疗史动态交互决定TFR结局。

核心结论

  • 日本研究验证了持续DMR后TFR的可行性及DMR持续时间的重要性,并提供了TFR相关机制的新见解,支持整合模型。

研究设计与样本

  • 综述日本关于CML的临床与转化研究,区分验证性发现与新生物学见解。

主要发现

  • 验证性研究证实持续DMR后TFR可行,DMR持续时间比快速达标更重要,重复停药尝试可行。
  • 日本研究提供白血病干细胞持续、达沙替尼相关免疫重塑、遗传免疫遗传决定因素、适应性免疫监视和TFR资格实用生物标志物的机制见解。

临床怎么用

  • 利用持续DMR时长评估TFR资格,考虑重复停药尝试,并关注免疫遗传背景和免疫能力对TFR的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment-free remission (TFR) has become a major therapeutic goal in patients with chronic myeloid leukemia (CML). Japanese clinical and translational studies have contributed substantially to this field. Here, we review Japanese studies and distinguish between findings that corroborate internationally established concepts and those that provide novel biological insights. Confirmatory studies demonstrated the feasibility of TFR after sustained deep molecular response (DMR), established DMR duration as a more important determinant of durable remission than rapid attainment, and confirmed the feasibility of repeated discontinuation attempts. Together, these findings support the concept that sustained DMR provides sufficient time for both continued reduction of residual disease burden and progressive restoration of immune surveillance. Beyond these observations, Japanese studies have provided important mechanistic insights into leukemic stem cell persistence, dasatinib-associated immune remodeling, inherited immunogenetic determinants of TFR, adaptive immune surveillance, and practical biomarkers of TFR eligibility. Collectively, these findings support an integrated model of TFR in which inherited immunogenetic background, immune competence, leukemic stem cell persistence, and treatment history interact dynamically to determine clinical outcomes. Ongoing studies, including ASSET-CML and ASC4Edit Japan, may further translate these insights into more individualized and durable TFR strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fujita M, Ureshino H, Kimura S, et al. Chronic myeloid leukemia in a global context: confirmatory findings and novel discoveries from a refined Japanese Cohort. Leukemia. 2026. PMID: 42839072. doi:10.1038/s41375-026-03155-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。